JPMorgan Chase & Co. Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $165.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price cut by JPMorgan Chase & Co. from $174.00 to $165.00 in a research note released on Wednesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other analysts have also recently issued reports about the company. Cantor Fitzgerald dropped their price target on Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating on the stock in a research report on Wednesday. StockNews.com lowered shares of Ascendis Pharma A/S from a hold rating to a sell rating in a report on Tuesday, August 13th. Bank of America boosted their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a buy rating in a report on Wednesday. Evercore ISI upgraded shares of Ascendis Pharma A/S to a strong-buy rating in a report on Monday, August 26th. Finally, Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 price objective for the company. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average target price of $187.08.

Ascendis Pharma A/S Stock Up 0.1 %

Shares of ASND opened at $119.15 on Wednesday. The business’s 50 day moving average price is $134.38 and its 200-day moving average price is $138.20. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The stock has a market cap of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ASND. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S in the 4th quarter worth $25,000. Gilbert & Cook Inc. boosted its holdings in Ascendis Pharma A/S by 8.4% in the 4th quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock worth $357,000 after buying an additional 220 shares during the period. Jump Financial LLC bought a new position in Ascendis Pharma A/S in the 4th quarter worth $1,681,000. Massachusetts Financial Services Co. MA boosted its holdings in Ascendis Pharma A/S by 20.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after buying an additional 254,749 shares during the period. Finally, First Turn Management LLC bought a new position in Ascendis Pharma A/S in the 4th quarter worth $19,092,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.